Bevacizumab is a targeted drug indicated for a variety of tumors. It exerts its action by inhibiting the biological activity of human vascular endothelial growth factor, whose target of action is VEGF, and its use reduces tumor microangiogenesis and inhibits the progression of metastases. It is currently used in metastatic colorectal cancer and non-small cell lung cancer (except for the treatment of squamous lung cancer). The clinically recommended dose is: for metastatic colorectal cancer in combination with chemotherapy, 5 mg/kg is recommended, administered once every two weeks. For advanced metastatic or recurrent non-small cell lung cancer, the recommended dose is 15 mg/kg given every three weeks in combination with paclitaxel or 7.5 mg/kg given every three weeks in combination with pemetrexed. Continuation of bevacizumab therapy is recommended until disease progression or intolerable toxicity occurs. The major adverse reactions to bevacizumab, manifest as bleeding, hypertension, and proteinuria. If serious adverse reactions occur, the drug should be discontinued immediately and treated symptomatically.